A court has slapped private health insurer Bupa with a $35 million penalty after it admitted to misleading thousands of customers about their benefits for over five years.
Setting up another potential legal fight, Mayne Pharma has said US drug maker Cosette did not validly terminate their $672 million merger agreement, which failed to receive FIRB approval.
Johnson & Johnson-owned Janssen has secured an injunction against drug maker Juno Pharmaceuticals, halting the release of Juno’s generic version of schizophrenia drug Invega Sustenna.
Ramsay Health Care has lost its challenge to development approval for a community health care services centre near its Greenslopes Hospital in Brisbane, with a court finding the centre would not interfere with the hospital’s operations.
The Full Federal Court has upheld a decision revoking Otsuka Pharmaceuticals’ patent extension for an injectable version of antipsychotic drug Abilify, finding the patent expired last year.
Nine wants indemnity costs against celebrity surgeon Munjed Al Muderis, claiming his defamation case over reports critical of his promotion of an experimental procedure, which the court found were substantially true, was an abuse of process.
Kennedys has lured a lawyer away from Wotton Kearney to join the healthcare practice in its Brisbane office.
German pharmaceutical company Heidelberg Pharma has filed a lawsuit against Australian drug maker Telix alleging breach of a licence agreement for its kidney cancer diagnostic drug Zircaix.
Treasurer Jim Chalmers has blocked Cosette’s $672 million takeover of Mayne Pharma on national interest grounds after the US drug maker threatened to close a critical drug facility in Adelaide.
The Takeovers Panel has found Cosette cannot close a Mayne Pharma drug manufacturing plant in Adelaide, another win for Mayne in its push to block the US drug maker from walking away from their $672 million merger.